NCT07745530 Platelets Target the Circulating HIV Reservoir: Implications for Immunological Failure
| NCT ID | NCT07745530 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tourcoing Hospital |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-04-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HIV/AIDS is a chronic disease that is difficult to eradicate because the virus persists as proviral DNA integrated into the host cells. Despite antiretroviral therapy, proviral DNA persists in lymphoid and myeloid reservoirs, whether circulating (memory CD4+ T cells) or tissue-based (macrophages). HIV reservoirs are highly heterogeneous, making it difficult to identify a specific biomarker or cell profile for a given reservoir. A distinctive feature of HIV reservoirs may be the selective interaction between reservoir cells and platelets. The presence of HIV in platelets could impact disease progression, particularly by triggering the reversal of HIV latency and leading to residual viral production. The frequency of platelets containing circulating virus in the blood is approximately 0.1% of the total platelet volume. Although seemingly negligible, this would represent a daily input of 10⁸ platelets harboring the virus. Furthermore, patients whose platelets contain HIV are primarily those with persistent immunological failure, known as "immunological non-responders" (InR). The regulation of the size (number and frequency) of the HIV reservoir by platelets is not known. However, HIV-containing platelets form more conjugates with CD4+ T cells than HIV-free platelets. While HIV-containing platelets do not productively infect cells, they induce metabolic dysfunction in CD4+ T cells (aerobic glycolysis). Increased aerobic glycolysis is a hallmark of T cell activation and senescence. This suggests an interconnection between the presence of the virus in platelets, the size of the reservoir, and immune dysfunction in HIV.
Eligibility Criteria
Inclusion Criteria: * Adult patients living with HIV with an undetectable viral load for more than 2 years * Beneficiary of a social security scheme or rightful claimant; * Patients able to read and understand the information sheet; * Having signed the consent form. Exclusion Criteria: * being unable to give free and informed consent; * pregnant or breastfeeding woman; * being under guardianship, curatorship, or a protection mandate;
Contact & Investigator
Olivier Robineau, MD, PhD
PRINCIPAL INVESTIGATOR
Centre Hospitalier de Tourcoing
Frequently Asked Questions
Who can join the NCT07745530 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07745530 currently recruiting?
Yes, NCT07745530 is actively recruiting participants. Contact the research team at jjvitagliano@ch-tourcoing.fr for enrollment information.
Where is the NCT07745530 trial being conducted?
This trial is being conducted at Tourcoing, France.
Who is sponsoring the NCT07745530 clinical trial?
NCT07745530 is sponsored by Tourcoing Hospital. The principal investigator is Olivier Robineau, MD, PhD at Centre Hospitalier de Tourcoing. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.